BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Urbonas G, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.Medicina (Kaunas). 2019;55. [PMID: 30650565 DOI: 10.3390/medicina55010015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zawawi NA, Abdul Halim Zaki I, Ming LC, Goh HP, Zulkifly HH. Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation. Front Cardiovasc Med 2021;8:736143. [PMID: 34869639 DOI: 10.3389/fcvm.2021.736143] [Reference Citation Analysis]
2 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
3 Rush KL, Burton L, Van Der Merwe F, Hatt L, Galloway C. Atrial fibrillation care in rural communities: a mixed methods study of physician and patient perspectives. BMC Fam Pract 2019;20:144. [PMID: 31651259 DOI: 10.1186/s12875-019-1029-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
4 Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Troy K, Schiano T, Mascarenhas J. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv 2020;4:655-66. [PMID: 32078681 DOI: 10.1182/bloodadvances.2019001310] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
5 Martín-Sánchez RÁ, Lorenzo-Villalba N, Calvo-Elías AE, Dubón-Peralta EE, Chocrón-Benbunan CE, Cano-de Luque CM, López-García L, Rivas-Molinero M, Outón-González C, Marco-Martínez J, Calvo-Manuel E, Andres E, Méndez-Bailón M. Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine. Medicina (Kaunas) 2021;57:365. [PMID: 33918627 DOI: 10.3390/medicina57040365] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Wen X, Wang S, Taveira TH, Akhlaghi F. Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH). PLoS One 2021;16:e0251665. [PMID: 34525124 DOI: 10.1371/journal.pone.0251665] [Reference Citation Analysis]
7 Yimer NS, Abiye AA, Hussen SU, Tadesse TA. Anticoagulation Control, Outcomes, and Associated Factors in Patients with Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia. Clin Appl Thromb Hemost 2021;27:10760296211049786. [PMID: 34724849 DOI: 10.1177/10760296211049786] [Reference Citation Analysis]
8 Costa Viana C, da Silva Praxedes MF, Freitas Nunes de Sousa WJ, Bartolazzi F, Sousa Vianna M, Padilha da Silva JL, Parreiras Martins MA. Sex-influence on the time in therapeutic range (TTR) during oral anticoagulation with coumarin derivatives: Systematic review and meta-analysis. Br J Clin Pharmacol 2021. [PMID: 33973668 DOI: 10.1111/bcp.14892] [Reference Citation Analysis]